Charles Schwab’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.09M | Sell |
909,590
-195,299
| -18% | -$664K | ﹤0.01% | 2523 |
|
|
2025
Q1 | $4.43M | Buy |
1,104,889
+41,899
| +4% | +$168K | ﹤0.01% | 2318 |
|
|
2024
Q4 | $6.9M | Buy |
1,062,990
+32,028
| +3% | +$208K | ﹤0.01% | 2180 |
|
|
2024
Q3 | $5.71M | Buy |
1,030,962
+113,127
| +12% | +$627K | ﹤0.01% | 2297 |
|
|
2024
Q2 | $5.12M | Buy |
917,835
+16,842
| +2% | +$94K | ﹤0.01% | 2350 |
|
|
2024
Q1 | $6.05M | Buy |
900,993
+20,955
| +2% | +$141K | ﹤0.01% | 2216 |
|
|
2023
Q4 | $8.03M | Buy |
880,038
+44,345
| +5% | +$404K | ﹤0.01% | 2106 |
|
|
2023
Q3 | $4.61M | Buy |
835,693
+136,201
| +19% | +$752K | ﹤0.01% | 2296 |
|
|
2023
Q2 | $5.97M | Buy |
699,492
+30,818
| +5% | +$263K | ﹤0.01% | 2161 |
|
|
2023
Q1 | $6.15M | Buy |
668,674
+613
| +0.1% | +$5.63K | ﹤0.01% | 2105 |
|
|
2022
Q4 | $6.82M | Buy |
668,061
+13,399
| +2% | +$137K | ﹤0.01% | 2044 |
|
|
2022
Q3 | $9.64M | Buy |
654,662
+339,406
| +108% | +$5M | ﹤0.01% | 1855 |
|
|
2022
Q2 | $3.38M | Buy |
315,256
+25,410
| +9% | +$273K | ﹤0.01% | 2361 |
|
|
2022
Q1 | $3.13M | Buy |
289,846
+184,142
| +174% | +$1.99M | ﹤0.01% | 2489 |
|
|
2021
Q4 | $1.73M | Buy |
105,704
+2,714
| +3% | +$44.3K | ﹤0.01% | 2745 |
|
|
2021
Q3 | $2.21M | Buy |
+102,990
| New | +$2.21M | ﹤0.01% | 2675 |
|